Markesbery W. R. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997; 23(1):134–47. doi:10.1016/S0891-5849(96)00629-6. Markesbery W. R. Oxidative alterations in Alzheimer’s disease. Brain Pathol. 1999 Jan; 9(1): 133–46. doi:10.1111/j.1750–3639.1999.tb00215.x. Muller W. E., et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease-therapeutic aspects. Mol Neurobiol. 2010 Jun; 41(2–3):159–71. doi:10.1007/s12035-010-8141-5.
Munch G., et al. Alzheimer’s disease — synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna). 1998; 105(4–5):439–61. doi:10.1007/s007020050069.
Nia S. S., et al. New pathogenic variations of mitochondrial DNA in Alzheimer disease! [letter]. J Res Med Sci. 2013 Mar; 18(3):269.
Nicotera P., Leist M., Manzo L. Neuronal cell death: a demise with different shapes. Trends Pharmacol Sci. 1999 Feb 1; 20(2):46–51. doi:10.1016/ S0165-6147(99)01304-8.
Ogawa M, et al. Altered energy metabolism in Alzheimer’s disease. J Neurol Sci. 1996 Jul; 139(1):78–82. doi:10.1016/0022-510X(96)00033-0.
Sery O., et al. Molecular mechanisms of neuropathological changes in Alzheimer’s disease: a review. Folia Neuropathol. 2013; 51(1):1–9. doi:10.5114/fn.2013.34190.
Smith M. A., et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997 Apr 15; 17(8):2653–7.
Sochocka M., et al. Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer’s disease: new approach to therapy. CNS Neurol Disord Drug Targets. 2013 Sep; 12(6):870–81. Epub Feb 27. doi:1 0.2174/18715273113129990072.
Wang X., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci. 2009 Jul 15; 29(28):9090–103. doi:10.1523/ JNEUROSCI.
Webster M. T., et al. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm. 1998 Nov; 105(8–9):839–53. doi:10.1007 /s007020050098.
Ying W. Deleterious network: a testable pathogenetic concept of Alzheimer’s disease. Gerontology. 1997; 43:242–53. doi:10.1159/000213856.
Переедание и болезнь Альцгеймера
Adeghate E., Donath T., Adem A. Alzheimer disease and diabetes mellitus: do they have anything in common? Curr Alzheimer Res. 2013 Jul; 10(6):609–17. Epub Apr 29. doi:10.2174 /15672050113109990009.
Cetinkalp S., Simsir I. Y., Ertek S. Insulin resistance in brain and possible therapeutic approaches. Curr Vasc Pharmacol. 2014; 12(4):553–64. Epub Apr 25. doi:10.2174/1570161112999140206 130426.
Geda Y. E. Abstract 3431. Paper presented at: American Academy of Neurology (AAN) 64th Annual Meeting; 2012 Apr 21–28; New Orleans, Louisiana. Mastrogiacomo F., Bergeron C., Kish E. J. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. J Neurochem. 1993 Dec; 61(6):2007–14. doi:10.1111/j.1471–4159.1993.tb07436.x.
Болезнь Паркинсона: новый взгляд на терапию ДОФА-содержащими препаратами
Abou-Sleiman P. M., Muqit M. M, Wood N. W. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 2006 Mar; 7(3):207–19. doi:10.1038/nrn1868.
Beal M. F. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S189–S194. doi:10.1016/S1353-8020(09) 70812-0.
Beal M. F., et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998 Feb; 783(1):109–14. doi:10.1016/S0006-8993(97)01192-X.
Bender A., et al. TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson’s disease. PLoS One. 2013 Apr 23; 8(4):e62277.
Berndt N., Holzhutter H. G., Bulik S. Implications of enzyme deficiencies on the mitochondrial energy metabolism and ROS formation of neurons involved in rotenone-induced Parkinson’s disease: A model-based analysis. FEBS J. 2013 Sep 12; 280(20):5080–93. Epub 2013 Aug 13. doi:10.1111/ febs.12480.
Dolle C., et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016 Nov 22; 7:13548.
Ebadi M., et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson’s disease. 2001. Biol Signals Recept 10:224–53. doi:10.1038/ncomms13548.
Freeman D., et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One. 2013 Apr 25; 8(4):e62143.
